Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
As it happened yesterday, WYPR hosted a "bio-ethicist" who was promoting a Novartis CRSPR (gene editing) "therapy" now that the FDA has approved such for marketing.
Novartis says there will be no charge if a patient doesn't respond to the therapy within a month. ... Previous estimates predicted a price tag between $600,000 to $750,000.

USD 500,000 is the list price quoted on-air for a single course of this therapy a/k/a "living drug" a/k/a "biologic". Efficacy and morbidity of said technique is unknown, but promising, based on trials with a rare form of leukemia: "An estimated 3,100 patients aged 20 and younger in the U.S. are diagnosed with acute lymphoblastic leukemia each year, making it the most common childhood cancer")

Diversity is the key to economic and political evolution.
by Cat on Thu Oct 5th, 2017 at 03:36:11 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series